10,744 Shares in LeMaitre Vascular, Inc. $LMAT Purchased by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio acquired 10,744 shares of LeMaitre Vascular, Inc. for approximately $892,000 during the second quarter.
• LeMaitre Vascular reported a 15% revenue increase in the last quarter, with earnings per share of $0.60, surpassing analysts' expectations of $0.57.
• LeMaitre Vascular's quarterly dividend of $0.20 reflects a 0.9% yield, with an annualized payout of $0.80 and a 38.83% payout ratio.

Public Employees Retirement System of Ohio purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,744 shares of the medical instruments supplier's stock, valued at approximately $892,000.

Several other large investors also recently modified their holdings of LMAT. Caitlin John LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $1,297,000. Annex Advisory Services LLC boosted its stake in shares of LeMaitre Vascular by 535.2% in the 2nd quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier's stock valued at $18,243,000 after purchasing an additional 185,085 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of LeMaitre Vascular by 1.1% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 22,282 shares of the medical instruments supplier's stock valued at $1,851,000 after purchasing an additional 245 shares in the last quarter. Wesbanco Bank Inc. boosted its position in LeMaitre Vascular by 103.6% in the second quarter. Wesbanco Bank Inc. now owns 11,400 shares of the medical instruments supplier's stock valued at $947,000 after buying an additional 5,800 shares in the last quarter. Finally, Strs Ohio bought a new stake in LeMaitre Vascular during the first quarter worth about $168,000. 84.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LMAT shares. Cantor Fitzgerald lifted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a "buy (b-)" rating on shares of LeMaitre Vascular in a research report on Saturday, September 27th. Finally, Barrington Research restated an "outperform" rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Tuesday, September 23rd. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $97.60.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $87.85 on Monday. The company has a fifty day moving average price of $91.66 and a 200 day moving average price of $86.29. The firm has a market cap of $1.99 billion, a PE ratio of 42.65, a PEG ratio of 2.26 and a beta of 0.77. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.LeMaitre Vascular's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular's payout ratio is presently 38.83%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director John A. Roush sold 6,561 shares of the firm's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the transaction, the director owned 2,916 shares in the company, valued at approximately $274,104. The trade was a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,815 shares of company stock valued at $11,280,206. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.